Article Text

Download PDFPDF
Original article
Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989–2012: a matched case–control study
  1. Jiajia Zhang1,2,
  2. Charles Haines3,
  3. Alastair J M Watson4,5,
  4. Andrew R Hart4,5,
  5. Mary Jane Platt4,
  6. Drew M Pardoll1,2,
  7. Sara E Cosgrove3,
  8. Kelly A Gebo3,6,
  9. Cynthia L Sears1,3
  1. 1 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  2. 2 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  3. 3 Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  4. 4 Department of Medicine, University of East Anglia Norwich Medical School, Norwich, Norfolk, UK
  5. 5 Department of Gastroenterology, Norfolk and Norwich University Hospital NHS Trust, Norwich, Norfolk, UK
  6. 6 Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
  1. Correspondence to Cynthia L Sears, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine Baltimore, MD 21287, USA; csears{at}jhmi.edu

Footnotes

  • JZ and CH contributed equally.

  • KAG and CLS contributed equally.

  • Contributors Study concept and design; acquisition, analysis or interpretation of data: all authors. Drafting of the manuscript: JZ, CH, CS. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: JZ, CH. Obtained funding: CS. Administrative, technical or material support: CS. Study supervision: SC, KG, CS.

  • Funding This study was funded by the Johns Hopkins Fisher Center Discovery Program and Bloomberg~Kimmel Institute for Cancer Immunotherapy.

  • Competing interests DP reports grant and patent royalties through institution from Bristol Myers Squibb, grant from Compugen, stock from Trieza Therapeutics and Dracen Pharmaceuticals, and founder equity from Potenza; being consultant for Aduro Biotech, Amgen, Astra Zeneca (Medimmune/Amplimmune), Bayer, DNAtrix, Dynavax Technologies Corporation, Ervaxx, FLX Bio, Rock Springs Capital, Janssen, Merck, Tizona, and Immunomic-Therapeutics; being on the scientific advisory board of Five Prime Therapeutics, Camden Nexus II, WindMil; being on the board of director for Dracen Pharmaceuticals outside the submitted work. SC reports being consultant for Novartis and Theravance outside the submitted work. CS reports a grant from Bristol Myers Squibb for microbiome research outside the submitted work.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Not required.

View Full Text

Statistics from Altmetric.com

Footnotes

  • JZ and CH contributed equally.

  • KAG and CLS contributed equally.

  • Contributors Study concept and design; acquisition, analysis or interpretation of data: all authors. Drafting of the manuscript: JZ, CH, CS. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: JZ, CH. Obtained funding: CS. Administrative, technical or material support: CS. Study supervision: SC, KG, CS.

  • Funding This study was funded by the Johns Hopkins Fisher Center Discovery Program and Bloomberg~Kimmel Institute for Cancer Immunotherapy.

  • Competing interests DP reports grant and patent royalties through institution from Bristol Myers Squibb, grant from Compugen, stock from Trieza Therapeutics and Dracen Pharmaceuticals, and founder equity from Potenza; being consultant for Aduro Biotech, Amgen, Astra Zeneca (Medimmune/Amplimmune), Bayer, DNAtrix, Dynavax Technologies Corporation, Ervaxx, FLX Bio, Rock Springs Capital, Janssen, Merck, Tizona, and Immunomic-Therapeutics; being on the scientific advisory board of Five Prime Therapeutics, Camden Nexus II, WindMil; being on the board of director for Dracen Pharmaceuticals outside the submitted work. SC reports being consultant for Novartis and Theravance outside the submitted work. CS reports a grant from Bristol Myers Squibb for microbiome research outside the submitted work.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.